Predictors of COVID-19 perceived susceptibility: insights from population-based self-reported survey during lockdown in the United States.


Journal

Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384

Informations de publication

Date de publication:
May 2022
Historique:
received: 20 08 2021
revised: 01 11 2021
accepted: 16 03 2022
pubmed: 17 4 2022
medline: 12 5 2022
entrez: 16 4 2022
Statut: ppublish

Résumé

The COVID-19 pandemic during lockdown has highlighted the importance of identifying individuals most at risk of infection with SARS-CoV-2, underscoring the need to assess factors contributing to susceptibility to disease. With the rapidly evolving nature of the pandemic and its new variants, there is an inadequate understanding on whether there are certain factors such as a specific symptom or collection of symptoms that combined with life-style behaviors may be useful to predict susceptibility. The study aims to explore such factors from pre-vaccination data to guide public health response to potential new waves. An anonymous electronic survey was distributed through social media during the lockdown period in the United States from April to June 2020. Respondents were questioned regarding COVID testing, presenting symptoms, demographic information, comorbidities, and confirmation of COVID-19 test results. Stepwise logistic regression was used to identify predictors for COVID-19 perceived susceptibility. Selected classifiers were assessed for prediction performance using area under receiver operating characteristic (AUROC) curve analysis. A total of 130 participants deemed as susceptible because they self-reported their perception of having COVID-19 (but without the evidence of positive test) were compared with 130 individuals with documented negative test results. Participants had a mean age of 45 years, and 165 (63%) were female. Final multivariable model showed significant associations with perceived susceptibility for the following variables: fever (OR:33.5; 95%CI: 3.9,85.9), body ache (OR:3.0; 95%CI:1.1,6.4), contact history (OR:2.7; 95%CI:1.1,6.4), age> 50 (OR:2.7; 95%CI:1.1, 6.6) and smoking (OR:3.3; 95%CI: 1.2,9.1) after adjusting for other symptoms and presence of comorbid conditions. The AUROC ranged from poor to fair (0.65-0.76) for cluster of symptoms but improved to a good model (AUROC = 0.803) after inclusion of sociodemographic and lifestyle behaviors e.g., age and smoking tobacco. Fever and body aches suggest association with perceived COVID-19 susceptibility in the presence of demographic and lifestyle behaviors. Using other constitutional and respiratory symptoms with fever and body aches, the parsimonious classifier correctly predicts 80.3% of COVID-19 perceived susceptibility. A larger cohort of respondents will be needed to study and refine classifier performance in future lockdowns and with expected surge of new variants of COVID-19 pandemic.

Sections du résumé

BACKGROUND BACKGROUND
The COVID-19 pandemic during lockdown has highlighted the importance of identifying individuals most at risk of infection with SARS-CoV-2, underscoring the need to assess factors contributing to susceptibility to disease. With the rapidly evolving nature of the pandemic and its new variants, there is an inadequate understanding on whether there are certain factors such as a specific symptom or collection of symptoms that combined with life-style behaviors may be useful to predict susceptibility. The study aims to explore such factors from pre-vaccination data to guide public health response to potential new waves.
METHODS METHODS
An anonymous electronic survey was distributed through social media during the lockdown period in the United States from April to June 2020. Respondents were questioned regarding COVID testing, presenting symptoms, demographic information, comorbidities, and confirmation of COVID-19 test results. Stepwise logistic regression was used to identify predictors for COVID-19 perceived susceptibility. Selected classifiers were assessed for prediction performance using area under receiver operating characteristic (AUROC) curve analysis.
RESULTS RESULTS
A total of 130 participants deemed as susceptible because they self-reported their perception of having COVID-19 (but without the evidence of positive test) were compared with 130 individuals with documented negative test results. Participants had a mean age of 45 years, and 165 (63%) were female. Final multivariable model showed significant associations with perceived susceptibility for the following variables: fever (OR:33.5; 95%CI: 3.9,85.9), body ache (OR:3.0; 95%CI:1.1,6.4), contact history (OR:2.7; 95%CI:1.1,6.4), age> 50 (OR:2.7; 95%CI:1.1, 6.6) and smoking (OR:3.3; 95%CI: 1.2,9.1) after adjusting for other symptoms and presence of comorbid conditions. The AUROC ranged from poor to fair (0.65-0.76) for cluster of symptoms but improved to a good model (AUROC = 0.803) after inclusion of sociodemographic and lifestyle behaviors e.g., age and smoking tobacco.
CONCLUSIONS CONCLUSIONS
Fever and body aches suggest association with perceived COVID-19 susceptibility in the presence of demographic and lifestyle behaviors. Using other constitutional and respiratory symptoms with fever and body aches, the parsimonious classifier correctly predicts 80.3% of COVID-19 perceived susceptibility. A larger cohort of respondents will be needed to study and refine classifier performance in future lockdowns and with expected surge of new variants of COVID-19 pandemic.

Identifiants

pubmed: 35429789
pii: S1876-0341(22)00067-3
doi: 10.1016/j.jiph.2022.03.012
pmc: PMC8941860
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-514

Subventions

Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests None declared.

Références

Int J Environ Res Public Health. 2021 Apr 20;18(8):
pubmed: 33924056
PLoS One. 2020 Oct 23;15(10):e0241165
pubmed: 33095811
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
Ann Behav Med. 2021 Jun 28;55(7):677-685
pubmed: 33991099
Expert Rev Clin Pharmacol. 2021 May;14(5):601-621
pubmed: 33705239
Cell Stem Cell. 2020 Dec 3;27(6):869-875.e4
pubmed: 33259798
Int Forum Allergy Rhinol. 2020 Jul;10(7):806-813
pubmed: 32279441
Expert Rev Vaccines. 2021 Apr;20(4):365-373
pubmed: 33851875
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
BMJ Glob Health. 2020 Jun;5(6):
pubmed: 32532758
Turk J Med Sci. 2020 Apr 15;50(SI-1):571-577
pubmed: 32293835
Viruses. 2020 May 26;12(6):
pubmed: 32466458
Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759
pubmed: 32663409
Nature. 2021 Jan;589(7843):500-501
pubmed: 33479534
Cureus. 2020 Aug 3;12(8):e9540
pubmed: 32905500
Ann Epidemiol. 2021 Jun;58:7-14
pubmed: 33691088
PLoS One. 2020 Nov 4;15(11):e0240399
pubmed: 33147219
Lancet Infect Dis. 2020 Sep;20(9):e245-e249
pubmed: 32687805
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Int Forum Allergy Rhinol. 2020 Jul;10(7):832-838
pubmed: 32363809
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Gastroenterology. 2020 Sep;159(3):1161-1163.e2
pubmed: 32422209
medRxiv. 2021 Feb 28;:
pubmed: 33655271
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Soc Sci Med. 2021 Mar;272:113638
pubmed: 33414032
BMJ Open. 2020 Oct 5;10(10):e039887
pubmed: 33020106
Am J Prev Med. 2000 Apr;18(3):215-8
pubmed: 10722987
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Int J Environ Res Public Health. 2021 Apr 12;18(8):
pubmed: 33921217
mBio. 2021 Feb 9;12(1):
pubmed: 33563817
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Am J Infect Control. 2021 Feb;49(2):238-246
pubmed: 32659414
JAMA. 2021 Mar 2;325(9):829-830
pubmed: 33512381
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
BMJ Open. 2020 Dec 22;10(12):e044642
pubmed: 33371050
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Nat Hum Behav. 2020 Sep;4(9):972-982
pubmed: 32848231
BMJ. 2020 Dec 16;371:m4857
pubmed: 33328153
J Asthma. 2022 May;59(5):866-879
pubmed: 33556287
Head Neck. 2020 Jul;42(7):1583-1590
pubmed: 32437033
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052841

Auteurs

Syed Ahsan Raza (SA)

Department of Medicine, Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States. Electronic address: syed.raza@bcm.edu.

Xiaotao Zhang (X)

Department of Medicine, Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States; Humana Integrated Health Systems Sciences Institute, Houston, TX, United States. Electronic address: Xiaotao.Zhang@bcm.edu.

Abiodun Oluyomi (A)

Department of Medicine, Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States. Electronic address: Abiodun.Oluyomi@bcm.edu.

Omolola E Adepoju (OE)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Health Systems and Population Health Science, University of Houston College of Medicine, Houston, TX, United States. Electronic address: oadepoju@central.uh.edu.

Ben King (B)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Health Systems and Population Health Science, University of Houston College of Medicine, Houston, TX, United States. Electronic address: kingb@Central.UH.EDU.

Christopher I Amos (CI)

Department of Medicine, Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States. Electronic address: Chris.Amos@bcm.edu.

Hoda Badr (H)

Department of Medicine, Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States. Electronic address: Hoda.Badr@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH